Analysts Issue Forecasts for DRTS Q1 Earnings

Alpha Tau Medical Ltd. (NASDAQ:DRTS) – Equities research analysts at HC Wainwright issued their Q1 2027 EPS estimates for Alpha Tau Medical in a research report issued to clients and investors on Wednesday, May 20th. HC Wainwright analyst Y. Chen expects that the company will earn ($0.14) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Alpha Tau Medical’s current full-year earnings is ($0.50) per share. HC Wainwright also issued estimates for Alpha Tau Medical’s Q4 2027 earnings at ($0.14) EPS.

Other equities research analysts also recently issued research reports about the stock. Citigroup raised their price objective on shares of Alpha Tau Medical from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, March 11th. LADENBURG THALM/SH SH raised their price objective on shares of Alpha Tau Medical from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Tuesday, May 12th. Piper Sandler raised their price objective on shares of Alpha Tau Medical from $5.00 to $8.00 and gave the company a “neutral” rating in a research report on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Alpha Tau Medical in a research report on Monday, April 20th. Finally, Zacks Research upgraded shares of Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 17th. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Alpha Tau Medical presently has a consensus rating of “Hold” and a consensus price target of $11.50.

Alpha Tau Medical Price Performance

Shares of NASDAQ:DRTS opened at $11.18 on Thursday. The company has a quick ratio of 7.45, a current ratio of 7.79 and a debt-to-equity ratio of 0.09. The company has a market cap of $983.95 million, a P/E ratio of -16.69 and a beta of 1.11. Alpha Tau Medical has a 52 week low of $2.81 and a 52 week high of $11.62. The company has a 50-day moving average price of $7.88 and a 200 day moving average price of $6.47.

Alpha Tau Medical (NASDAQ:DRTS) last announced its quarterly earnings data on Monday, May 18th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13).

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Mariner LLC increased its holdings in Alpha Tau Medical by 1.6% in the fourth quarter. Mariner LLC now owns 125,165 shares of the company’s stock valued at $620,000 after buying an additional 1,915 shares in the last quarter. Trifecta Capital Advisors LLC purchased a new position in Alpha Tau Medical in the fourth quarter valued at about $48,000. Levin Capital Strategies L.P. increased its holdings in Alpha Tau Medical by 6.3% in the third quarter. Levin Capital Strategies L.P. now owns 204,714 shares of the company’s stock valued at $923,000 after buying an additional 12,200 shares in the last quarter. Envestnet Asset Management Inc. purchased a new position in Alpha Tau Medical in the third quarter valued at about $62,000. Finally, Wells Fargo & Company MN increased its holdings in Alpha Tau Medical by 291.7% in the fourth quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock valued at $116,000 after buying an additional 17,500 shares in the last quarter. 2.65% of the stock is owned by hedge funds and other institutional investors.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.